Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapeutics, Inc. - Common Stock (NQ: ACRS )

1.351 +0.081 (+6.38%)
Streaming Delayed Price Updated: 11:36 AM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121,099
Open 1.270
Bid (Size) 1.350 (7)
Ask (Size) 1.360 (9)
Prev. Close 1.270
Today's Range 1.260 - 1.360
52wk Range 0.9515 - 5.170
Shares Outstanding 107,850,124
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and... 
Via Benzinga
Santa Rally, January Effect, And Top Stock Picks
Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas! 
Via Talk Markets
Topics Stocks / Equities

Performance

YTD
-45.52%
-45.52%
1 Month
-19.10%
-19.10%
3 Month
-47.02%
-47.02%
6 Month
+4.73%
+4.73%
1 Year
+15.47%
+15.47%

More News

Read More
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Via Benzinga
Level Up Your Trading: Inside The 4-Pillar Strategy Behind Triple-Digit Returns
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Aclaris Therapeutics: Q4 Earnings Insights
Via Benzinga
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
Via Benzinga
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Via Benzinga
War, Gold, And Opportunity: Uncovering Today’s Market Moves
Via Talk Markets
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Via MarketBeat
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Via Benzinga
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
Via Benzinga
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.